TRCT
EW icon

Tower Research Capital (TRC)’s Edwards Lifesciences EW Stock Holding History

Tower Research Capital (TRC)’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$498K Sell
6,221
-6,530
-51% -$538K 0.01% 916
2025
Q4 		$1.09M Buy
12,751
+1,765
+16% +$145K 0.03% 487
2025
Q3 		$854K Sell
10,986
-12,218
-53% -$955K 0.02% 580
2025
Q2 		$1.81M Sell
23,204
-3,218
-12% -$240K 0.05% 331
2025
Q1 		$1.92M Sell
26,422
-23,492
-47% -$1.68M 0.06% 296
2024
Q4 		$3.7M Buy
49,914
+20,069
+67% +$1.4M 0.07% 212
2024
Q3 		$1.97M Sell
29,845
-38,483
-56% -$2.8M 0.05% 285
2024
Q2 		$6.31M Buy
68,328
+56,017
+455% +$4.96M 0.11% 154
2024
Q1 		$1.18M Sell
12,311
-59,411
-83% -$4.99M 0.03% 454
2023
Q4 		$5.47M Buy
71,722
+27,707
+63% +$1.93M 0.07% 238
2023
Q3 		$3.05M Buy
44,015
+36,874
+516% +$2.96M 0.1% 193
2023
Q2 		$674K Sell
7,141
-3,946
-36% -$343K 0.02% 772
2023
Q1 		$917K Sell
11,087
-2,622
-19% -$206K 0.03% 497
2022
Q4 		$1.02M Sell
13,709
-42,433
-76% -$3.27M 0.04% 367
2022
Q3 		$4.64M Buy
56,142
+24,223
+76% +$2.33M 0.08% 207
2022
Q2 		$3.04M Sell
31,919
-55,261
-63% -$5.72M 0.07% 239
2022
Q1 		$10.3M Buy
87,180
+54,160
+164% +$6.08M 0.1% 178
2021
Q4 		$4.28M Buy
33,020
+16,162
+96% +$1.89M 0.07% 225
2021
Q3 		$1.91M Buy
16,858
+3,329
+25% +$380K 0.05% 280
2021
Q2 		$1.4M Sell
13,529
-35,912
-73% -$3.39M 0.04% 450
2021
Q1 		$4.14M Buy
49,441
+20,969
+74% +$1.77M 0.07% 258
2020
Q4 		$2.6M Buy
28,472
+10,812
+61% +$897K 0.08% 170
2020
Q3 		$1.41M Buy
17,660
+11,071
+168% +$864K 0.02% 660
2020
Q2 		$455K Sell
6,589
-18,371
-74% -$1.31M 0.02% 1112
2020
Q1 		$1.57M Buy
24,960
+24,381
+4,211% +$1.76M 0.1% 132
2019
Q4 		$45K Sell
579
-12,849
-96% -$1M ﹤0.01% 1406
2019
Q3 		$984K Sell
13,428
-27,288
-67% -$1.92M 0.07% 292
2019
Q2 		$2.51M Buy
40,716
+26,784
+192% +$1.62M 0.17% 80
2019
Q1 		$889K Buy
13,932
+5,064
+57% +$289K 0.05% 331
2018
Q4 		$453K Buy
8,868
+7,353
+485% +$372K 0.03% 448
2018
Q3 		$88K Sell
1,515
-19,107
-93% -$934K 0.01% 1424
2018
Q2 		$1M Buy
+20,622
New +$963K 0.06% 352
2018
Q1 		– Sell
-5,604
Closed -$210K – 3400
2017
Q4 		$210K Buy
5,604
+3,639
+185% +$134K 0.03% 546
2017
Q3 		$72K Buy
+1,965
New +$74.9K 0.01% 1654
2017
Q2 		– Sell
-426
Closed -$15.5K – 2912
2017
Q1 		$13K Sell
426
-20,814
-98% -$652K ﹤0.01% 1587
2016
Q4 		$663K Buy
21,240
+20,940
+6,980% +$678K 0.07% 285
2016
Q3 		$12K Sell
300
-5,106
-94% -$192K ﹤0.01% 1925
2016
Q2 		$180K Sell
5,406
-9,684
-64% -$331K 0.02% 734
2016
Q1 		$444K Buy
15,090
+13,869
+1,136% +$383K 0.07% 187
2015
Q4 		$32K Buy
+1,221
New +$31.7K 0.01% 822
2015
Q3 		– Sell
-516
Closed -$12K – 4209
2015
Q2 		$12K Buy
+516
New +$11.6K ﹤0.01% 2525
2014
Q4 		– Sell
-25,356
Closed -$432K – 4185
2014
Q3 		$432K Buy
25,356
+16,380
+182% +$259K 0.05% 290
2014
Q2 		$128K Sell
8,976
-26,676
-75% -$362K 0.02% 773
2014
Q1 		$441K Buy
35,652
+31,260
+712% +$361K 0.06% 230
2013
Q4 		$48K Buy
4,392
+2,454
+127% +$27.7K 0.01% 1421
2013
Q3 		$22K Sell
1,938
-5,850
-75% -$68.4K ﹤0.01% 2609
2013
Q2 		$87K Buy
+7,788
New +$92.2K 0.01% 580

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tower Research Capital (TRC)'s EW Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Edwards Lifesciences (EW) stake by 51% in Q1 2026, selling an estimated $538K and leaving 6,221 shares worth $498K. The position accounts for 0.01% of the portfolio, ranked #916.

Tower Research Capital (TRC) first reported a position in EW in Q2 2013 and has held it in 47 quarters since. The position peaked at $10.3M in Q1 2022. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Tower Research Capital (TRC) held 6,221 shares of Edwards Lifesciences worth $498K as of Q1 2026.
  • Tower Research Capital (TRC) sold 6,530 Edwards Lifesciences shares in Q1 2026, an estimated $538K.
  • Edwards Lifesciences made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #916 holding.
  • Tower Research Capital (TRC) first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 47 quarters since.
  • Tower Research Capital (TRC)'s Edwards Lifesciences position peaked at $10.3M in Q1 2022.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.